Published in Curr Opin Pharmacol on April 15, 2011
Nuclear PI3K signaling in cell growth and tumorigenesis. Front Cell Dev Biol (2015) 0.96
Microbial peptidyl-prolyl cis/trans isomerases (PPIases): virulence factors and potential alternative drug targets. Microbiol Mol Biol Rev (2014) 0.93
Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med (2012) 0.89
Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response. Oncotarget (2014) 0.86
Primate-specific melanoma antigen-A11 regulates isoform-specific human progesterone receptor-B transactivation. J Biol Chem (2012) 0.81
Mitochondria-nucleus shuttling FK506-binding protein 51 interacts with TRAF proteins and facilitates the RIG-I-like receptor-mediated expression of type I IFN. PLoS One (2014) 0.80
The cyclin D1-CDK4 oncogenic interactome enables identification of potential novel oncogenes and clinical prognosis. Cell Cycle (2014) 0.79
Increased cortical expression of FK506 binding protein-51 in HIV-associated neurocognitive disorders. J Neurovirol (2012) 0.77
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol (1997) 15.32
Cell signaling by receptor tyrosine kinases. Cell (2010) 12.39
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94
PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell (2005) 8.22
PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell (2007) 6.00
FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell (2009) 4.48
The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene (2008) 4.39
PI3K/Akt: getting it right matters. Oncogene (2008) 3.91
Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol (2002) 3.77
Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci U S A (1977) 3.25
Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat (2002) 2.95
A PP2A regulatory subunit regulates C. elegans insulin/IGF-1 signaling by modulating AKT-1 phosphorylation. Cell (2009) 2.61
Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res (2008) 2.58
PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res (2009) 2.32
The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem (2007) 2.24
FKBP family proteins: immunophilins with versatile biological functions. Neurosignals (2008) 1.94
Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther (2007) 1.90
Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes. Proc Natl Acad Sci U S A (2003) 1.58
The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. J Neurosci (2010) 1.57
FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. Mol Cell Biol (1995) 1.45
PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des (2010) 1.45
FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells. Mol Cell Biol (2010) 1.36
AKT signaling in physiology and disease. Curr Top Microbiol Immunol (2010) 1.35
Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov (2010) 1.30
New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin Investig Drugs (2011) 1.15
The role of FKBP5 in cancer aetiology and chemoresistance. Br J Cancer (2010) 1.14
Transferred nuclear Overhauser effect analyses of membrane-bound enkephalin analogues by 1H nuclear magnetic resonance: correlation between activities and membrane-bound conformations. Biochemistry (1990) 1.00
FK506 binding proteins as targets in anticancer therapy. Anticancer Agents Med Chem (2010) 0.95
Emerging role of FKBP51 in AKT kinase/protein kinase B signaling. Cell Cycle (2010) 0.93
Another role for the celebrity: Akt and insulin resistance. Circ Res (2005) 0.88